In this Q&A, Avihu Tamir, CEO of Kanabo Group (KNB ), the Israeli-based medicinal cannabis firm, which earlier this year made its debut on London’s main market, discusses the company’s milestones since August 2021 - from new partnerships and new formulas, to new licence facilities and efficacy trials - and how the cannabis market continues to evolve in Europe.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
